1950 Stemmons Freeway, Suite 5001
Dallas, TX 75207
The crux of the discovery platform of Reata is an assay that reveals, basically in real time, the effect that small molecules are having on the folding behavior of proteins. Reata aims to harness this capability to identify compounds that beneficially influence proteins known to underlie diseases that are prone to misfolding in specific ways. In the case of Alzheimer's disease, Reata is looking at amyloid-beta , the principal component in the plaques found in the brains of AD patients, and at tau, which forms protein inclusions, or tangles, involved in a number of neurodegenerative diseases.
1950 Stemmons Freeway, Suite 5001
Dallas, TX 75207
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.